Research Article

Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia/reperfusion Injury in Rats

Volume: 9 Number: 4 December 16, 2019
EN TR

Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia/reperfusion Injury in Rats

Abstract

Objective: The aim of this study is to prove whether or not the cannabinoid (CB)2 receptor agonist, which is known to be effective in anti-inflammatory effects and tried in various organ and/or tissue ischemia/reperfusion (I/R) injuries, works in the treatment of I/R injury, which is a replication of the damage caused by clinical ovarian torsion.

Materials and Methods: Rats were divided into five groups (n=6). After anesthesia, an approximately 2-cm incision was made in the lower abdominal region of the rats and both ovaries, uterine horns, and adnexa were occluded with a clamp for 30 min, except for the sham control group. After 3 h, both ovaries were surgically removed. Blood was collected for the measurement of cytokine levels in the serum.

Results: The induction of ovaries by I/R injury resulted in an increase in interleukin 1 beta, tumor necrosis factor alpha, and malondialdehyde levels and decrease in glutathione (GSH) levels in ovarian tissues and serum. The pretreatment of the CB2 receptor agonist decreased these cytokines levels in both ovarian tissues and serum. The GSH level in both was reduced by I/R injury, while the agonist increased the GSH level reduced by I/R injury. The administration of the antagonist reversed the curative effect of the agonist.

Conclusion: The results of this study support that the CB2 receptor agonist can be used to treat I/R injury, which is an imitation of ovarian torsion. However, no the clinical trial is a limitation of this study.

Keywords

Supporting Institution

Adiyaman University

Project Number

TIPFYL/2019-0001

References

  1. 1. Kurt RK, Dogan AC, Dogan M, et al. Protective effect of colchicine on ovarian ischemia-reperfusion injury: An experimental study. Reprod Sci. 2015;22(5):545-550. doi:10.1177/1933719114553065
  2. 2. Kolusari A, Okyay AG, Koçkaya EA. The Effect of Erythropoietin in Preventing Ischemia–Reperfusion Injury in Ovarian Tissue Transplantation. Reprod Sci. 2018;25(3):406-413. doi:10.1177/1933719117715127
  3. 3. Bayram S, Parlar A, Arslan SO. The curative effect of cannabinoid 2 receptor agonist on functional failure and disruptive inflammation caused by intestinal ischemia and reperfusion. Fundam Clin Pharmacol. August 2019. doi:10.1111/fcp.12502
  4. 4. Sayan H, Ozacmak VH, Altaner S, Aktas RG, Arslan SO. Protective Effects of L-Arginine on Rat Terminal Ileum Subjected to Ischemia/Reperfusion. J Pediatr Gastroenterol Nutr. 2008;46(1):29-35. doi:10.1097/01.mpg.0000304450.54057.96
  5. 5. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell Biology of Ischemia/Reperfusion Injury. In: International Review of Cell and Molecular Biology. Vol 298. ; 2012:229-317. doi:10.1016/B978-0-12-394309-5.00006-7
  6. 6. Esme H, Fidan H, Koken T, Solak O. Effect of lung ischemia–reperfusion on oxidative stress parameters of remote tissues. Eur J Cardio-Thoracic Surg. 2006;29(3):294-298. doi:10.1016/j.ejcts.2005.12.008
  7. 7. Draper HH, Hadley M. [43] Malondialdehyde determination as index of lipid Peroxidation. In: Oxygen Radicals in Biological Systems Part B: Oxygen Radicals and Antioxidants. Vol 186. Methods in Enzymology. Academic Press; 1990:421-431. doi:https://doi.org/10.1016/0076-6879(90)86135-I
  8. 8. Kumar V, Torben W, Mansfield J, et al. Cannabinoid Attenuation of Intestinal Inflammation in Chronic SIV-Infected Rhesus Macaques Involves T Cell Modulation and Differential Expression of Micro-RNAs and Pro-inflammatory Genes. Front Immunol. 2019;10:914. doi:10.3389/fimmu.2019.00914

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

December 16, 2019

Submission Date

September 28, 2019

Acceptance Date

December 5, 2019

Published in Issue

Year 2019 Volume: 9 Number: 4

APA
Bilgin Şahin, B., & Parlar, A. (2019). Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia/reperfusion Injury in Rats. Sakarya Medical Journal, 9(4), 679-686. https://doi.org/10.31832/smj.626204
AMA
1.Bilgin Şahin B, Parlar A. Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia/reperfusion Injury in Rats. Sakarya Medical Journal. 2019;9(4):679-686. doi:10.31832/smj.626204
Chicago
Bilgin Şahin, Buket, and Ali Parlar. 2019. “Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia Reperfusion Injury in Rats”. Sakarya Medical Journal 9 (4): 679-86. https://doi.org/10.31832/smj.626204.
EndNote
Bilgin Şahin B, Parlar A (December 1, 2019) Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia/reperfusion Injury in Rats. Sakarya Medical Journal 9 4 679–686.
IEEE
[1]B. Bilgin Şahin and A. Parlar, “Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia/reperfusion Injury in Rats”, Sakarya Medical Journal, vol. 9, no. 4, pp. 679–686, Dec. 2019, doi: 10.31832/smj.626204.
ISNAD
Bilgin Şahin, Buket - Parlar, Ali. “Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia Reperfusion Injury in Rats”. Sakarya Medical Journal 9/4 (December 1, 2019): 679-686. https://doi.org/10.31832/smj.626204.
JAMA
1.Bilgin Şahin B, Parlar A. Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia/reperfusion Injury in Rats. Sakarya Medical Journal. 2019;9:679–686.
MLA
Bilgin Şahin, Buket, and Ali Parlar. “Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia Reperfusion Injury in Rats”. Sakarya Medical Journal, vol. 9, no. 4, Dec. 2019, pp. 679-86, doi:10.31832/smj.626204.
Vancouver
1.Buket Bilgin Şahin, Ali Parlar. Protective Effect of Cannabinoid Type 2 Receptor Agonist Against Ovarian Ischemia/reperfusion Injury in Rats. Sakarya Medical Journal. 2019 Dec. 1;9(4):679-86. doi:10.31832/smj.626204

INDEXING & ABSTRACTING & ARCHIVING


  29985  30950  30951 30954 34273


30703 The published articles in SMJ are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.